Request Demo
Last update 15 Feb 2025
TGRX-814
Last update 15 Feb 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TGRX 814, TGRX-814, TGRX814 |
Target |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Bcl-xl inhibitors(Apoptosis regulator Bcl-X inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization  Shenzhen TargetRx, Inc.Startup |
Active Organization Shenzhen TargetRx, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with TGRX-814CTR20240015
一项评价 TGRX-814 单药及联合疗法治疗血液系统恶性肿瘤
患者的安全性、耐受性、药代动力学和初步疗效的单臂、开放、
剂量递增及扩展的 I/II 期临床试验
[Translation] A single-arm, open-label, dose-escalation and expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-814 monotherapy and combination therapy in patients with hematological malignancies
NCT06206174
A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
100 Clinical Results associated with TGRX-814
Login to view more data
100 Translational Medicine associated with TGRX-814
Login to view more data
100 Patents (Medical) associated with TGRX-814
Login to view more data
100 Deals associated with TGRX-814
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 13 May 2024 |
| Chronic Lymphocytic Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 13 May 2024 |
| Marginal Zone B-Cell Lymphoma | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 13 May 2024 |
| Small Lymphocytic Lymphoma | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 13 May 2024 |
| Waldenstrom Macroglobulinemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 13 May 2024 |
| Acute Myeloid Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 06 Mar 2024 |
| Adult Acute Lymphocytic Leukemia | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 06 Mar 2024 |
| Myelodysplastic Syndromes | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 06 Mar 2024 |
| Non-Hodgkin Lymphoma | Phase 2 | CN | Shenzhen TargetRx, Inc.Startup | 06 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free